Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (Nasdaq: GERN) is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. News about Geron frequently centers on its first-in-class telomerase inhibitor RYTELO (imetelstat), which is approved in the United States and the European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia.
On this page, readers can follow corporate announcements and scientific updates that shape the GERN investment story. Typical news items include financial guidance and quarterly results that discuss RYTELO net product revenue and operating expenses, strategic restructuring plans intended to support the company’s hematology focus, and details of equity grants made under Nasdaq inducement award rules. These disclosures provide insight into Geron’s commercial execution, cost structure and capital allocation.
Geron also issues frequent clinical and medical conference updates. Recent releases have highlighted data presented at the American Society of Hematology (ASH) Annual Meeting, including pooled analyses from the Phase 3 IMerge trial in LR-MDS, long-term outcomes data, and exploratory biomarker studies in myelofibrosis and advanced myelodysplastic neoplasms or acute myeloid leukemia. News about the IMpactMF Phase 3 trial in JAK-inhibitor relapsed/refractory myelofibrosis, as well as the IMbark, IMproveMF and IMpress studies, offers additional context on imetelstat’s development across myeloid malignancies.
Investors can also track leadership changes and investor relations events, such as executive appointments, board updates and participation in healthcare investor conferences. Together, these news items help explain how Geron is pursuing its stated priorities of driving RYTELO commercial growth, expanding access in LR-MDS markets outside the U.S. and advancing its pivotal myelofibrosis program. Bookmark this page to follow ongoing developments affecting GERN’s clinical programs, regulatory milestones, commercial performance and corporate strategy.
Geron Corporation (Nasdaq: GERN) announced that CEO Harout Semerjian will present at two investor conferences in November–December 2025. He will appear in a fireside chat at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 11:40 AM ET in New York, and at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 11:15 AM ET in Miami. A live webcast of each fireside chat will be available in the company’s Investors & Media Events section, and replays will be archived on the company website.
Geron (Nasdaq: GERN) announced five presentations accepted for ASH 2025 (Dec 6-9, Orlando) reporting new clinical and translational analyses of RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS) and myelofibrosis (MF).
Highlights include an oral IMerge Phase 3 analysis linking treatment-emergent cytopenias to clinical response in LR-MDS (Dec 7), a long-term IMerge poster with a ≥42-month overall survival trend versus placebo (Dec 6), MF biomarker and cytokine-response analyses from IMbark, an IMproveMF combination trial update, and an investigator-led interim IMpress study in high-risk MDS/AML.
Geron (Nasdaq: GERN) will release its third quarter 2025 financial results and business highlights before the market opens on Wednesday, November 5, 2025.
The company said the results will be posted via press release on its investor website and that management will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day. A live webcast and related presentation will be available and archived on the investor site for later playback.
Geron (Nasdaq: GERN) reported inducement equity awards to newly hired employees under Nasdaq Listing Rule 5635(c)(4).
On October 17, 2025 Geron granted awards covering 1,579,500 shares (1,553,000 stock options and 26,500 RSUs). On October 20, 2025 Geron granted awards covering 1,500,000 shares to one new hire. Options from October 17 carry an exercise price of $1.20; options from October 20 carry an exercise price of $1.27—each equal to the closing price on the grant date.
Options have a 10-year term and vest over 4 years (12.5% at six months, then monthly over 42 months). RSUs vest 25% annually over four years. Awards were granted by the Compensation Committee under Geron’s 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) announced executive leadership transitions on Oct 13, 2025. Andrew Grethlein (EVP, COO) and Jim Ziegler (EVP, CCO) will depart on Oct 15, 2025, with Grethlein moving to a consulting role. Effective Oct 20, 2025, Ahmed ElNawawi is appointed EVP, Chief Commercial Officer to lead U.S. commercial strategy for RYTELO. Three additional senior hires announced: Shantha Tyavanagimatt as SVP, Chief Technical Officer; Dawn Schottlandt as SVP, Investor Relations and Corporate Affairs; and Bryan Ridgell as SVP, Portfolio and Project Management and Chief of Staff (joined Oct 13, 2025).
The appointments emphasize commercial scale-up, technical operations, investor engagement, and portfolio management to support RYTELO commercialization and future portfolio expansion.
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, has granted equity awards totaling 966,000 shares to sixteen new employees as employment inducements. The awards, granted on September 17, 2025, include 644,000 stock options at $1.27 per share and 322,000 restricted stock units (RSUs).
The stock options have a ten-year term with a 4-year vesting schedule, starting with 12.5% vesting at six months and the remainder over 42 months. RSUs vest 25% annually over four years. These awards were approved under Nasdaq Listing Rule 5635(c)(4) through Geron's 2018 Inducement Award Plan.
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference in Boston, MA. The presentation is scheduled for September 4, 2025.
Investors can access a live webcast of the presentation through Geron's investor relations website at ir.geron.com. The webcast recording will remain available for replay for 30 days after the event.
Geron Corporation (Nasdaq: GERN) has granted equity awards totaling 522,000 shares to eleven new employees as employment inducement. The awards consist of 348,000 stock options at $1.45 per share and 174,000 restricted stock units (RSUs).
The stock options have a ten-year term with a 4-year vesting schedule, starting with 12.5% vesting after six months and the remainder vesting over 42 months. The RSUs vest 25% annually over four years. These awards were granted under Geron's 2018 Inducement Award Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
Geron Corporation (Nasdaq: GERN) has granted stock options to its new President and CEO, Harout Semerjian, as an inducement for employment. The grant includes options to purchase 11 million shares of common stock at $1.30 per share, equal to the closing price on August 7, 2025.
The options are structured in two tranches: 7 million shares vesting over 4 years with 12.5% vesting after 6 months, and 4 million shares vesting over 4 years with 25% vesting after one year. The options have a ten-year term and were granted under Geron's 2018 Inducement Award Plan.
Geron Corporation (Nasdaq: GERN) reported strong Q2 2025 financial results, highlighting $49.0 million in RYTELO® net product revenue, representing a 24% increase from Q1. The company announced the appointment of Harout Semerjian as President and CEO and reported significant commercial progress with over 1,000 ordering accounts.
Key financial metrics include a reduced net loss of $16.4 million ($0.02 per share), compared to $67.4 million in Q2 2024. The company maintains a strong cash position of $432.6 million. The Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis has reached 95% enrollment, with full enrollment expected by year-end 2025.